Therapeutic drug monitoring is a useful clinical decision aid in managing patients with inflammatory bowel disease treated with anti-tumor necrosis factor (anti-TNF). Various techniques are available to evaluate drug trough levels, and among these a point-of-care (POC) method has been proposed to overcome the limitations inherent to other methodologies. In this study we aimed to evaluate the capability of POC to discriminate between relapse and remission disease phases, and to assess the concordance of the POC and homogeneous mobility shift assay (HMSA) results.
Therapeutic drug monitoring in Crohn's disease patients treated with anti-TNF: a comparison of two techniques
Bodini, Giorgia;Demarzo, Maria Giulia;Djahandideh, Afscin;Ziola, Sebastiano;Testa, Tommaso;Giannini, Edoardo Giovanni
2022-01-01
Abstract
Therapeutic drug monitoring is a useful clinical decision aid in managing patients with inflammatory bowel disease treated with anti-tumor necrosis factor (anti-TNF). Various techniques are available to evaluate drug trough levels, and among these a point-of-care (POC) method has been proposed to overcome the limitations inherent to other methodologies. In this study we aimed to evaluate the capability of POC to discriminate between relapse and remission disease phases, and to assess the concordance of the POC and homogeneous mobility shift assay (HMSA) results.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Eur J Gastr Hep & IBD TL.pdf
accesso chiuso
Tipologia:
Documento in versione editoriale
Dimensione
744.87 kB
Formato
Adobe PDF
|
744.87 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
